Clinical Trial Update: A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating alisertib in extensive-stage small cell lung cancer is currently recruiting. The sponsor is Puma Biotechnology.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• Alisertib (alisertib)

Snippet

Sponsor: Puma Biotechnology, Inc. | Conditions: Small Cell Lung Cancer | Phase 2 | Status: RECRUITING